Search results
Prediction: These 2 Growth Stocks Could Triple By 2030
Motley Fool via Yahoo Finance· 4 days agoConsider, for instance, AXS-12, a potential treatment for cataplexy (sudden muscular weakness) in...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 2 days agoMarket and Future Outlook The biopharmaceutical landscape for rare genetic diseases is both...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoTokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2024. The full report
Regenex Bio eyes FDA meeting to confirm pivotal DMD trial
Clinical Trials Arena via Yahoo Finance· 6 days agoInitial strength and functional assessment data for both dose levels of the AFFINITY DUCHENNE trial...
Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
GuruFocus.com via Yahoo Finance· 1 day agoPositive Points Moleculin Biotech Inc (NASDAQ:MBRX) secured composition of matter patent protection for Annamycin, ensuring market exclusivity through 2040. Achieved orphan
Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Hi
Guru Focus· 2 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Moleculin Biotech Inc (MBRX, Financial) secured composition of matter patent protection for ...
SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
The Sun Chronicle· 6 days agoSN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 6 days agoREDWOOD CITY, Calif. & SANTA MONICA, Calif. - Kite, a Gilead Company (NASDAQ: GILD), and Arcellx,...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 2 days agoMoleculin Biotech, Inc. (NASDAQ:MBRX), in its first quarter 2024 earnings call, highlighted...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 6 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...